Abbott Labs Quarterly Valuation – June 2014 $ABT

500px-AbbottLaboratories.svgBenjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 5 Undervalued Companies for the Enterprising Investor Near 52 Week Lows.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a specific look at how Abbott Labs (ABT) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.
ABT Chart

ABT data by YCharts

Defensive Investor – must pass at least 6 of the following 7 tests: Score = 5/7

  1. Adequate Size of Enterprise – market capitalization of at least $2 billion – PASS
  2. Sufficiently Strong Financial Condition – current ratio greater than 2 – FAIL
  3. Earnings Stability – positive earnings per share for at least 10 straight years - PASS
  4. Dividend Record – has paid a dividend for at least 10 straight years - PASS
  5. Earnings Growth – earnings per share has increased by at least 1/3 over the last 10 years using 3 year averages at beginning and end of period – FAIL
  6. Moderate PEmg ratio – PEmg is less than 20 - PASS
  7. Moderate Price to Assets – PB ratio is less than 2.5 or PB x PEmg is less than 50 – FAIL

Enterprising Investor – must pass at least 4 of the following 5 tests or be suitable for a defensive investor: Score = 4/5

  1. Sufficiently Strong Financial Condition, Part 1 – current ratio greater than 1.5 – PASS
  2. Sufficiently Strong Financial Condition, Part 2 – Debt to Net Current Assets ratio less than 1.1 - PASS
  3. Earnings Stability – positive earnings per share for at least 5 years – PASS
  4. Dividend Record – currently pays a dividend - PASS
  5. Earnings growth – EPSmg greater than 5 years ago - FAIL

Valuation Summary

Key Data:

Recent Price $39.90
MG Value $8.74
MG Opinion Overvalued
Value Based on 3% Growth $35.82
Value Based on 0% Growth $21.00
Market Implied Growth Rate 3.83%
Net Current Asset Value (NCAV) -$0.23
PEmg 16.15
Current Ratio 1.76
PB Ratio 2.56

Balance Sheet – 3/31/2014

Current Assets $17,931,000,000
Current Liabilities $10,186,000,000
Total Debt $3,387,000,000
Total Assets $41,662,000,000
Intangible Assets $15,394,000,000
Total Liabilities $18,272,000,000
Outstanding Shares 1,501,940,000

Earnings Per Share

2014 (estimate) $2.16
2013 $1.50
2012 $3.75
2011 $3.02
2010 $2.96
2009 $3.69
2008 $3.03
2007 $2.31
2006 $1.12
2005 $2.16
2004 $2.02

Earnings Per Share – ModernGraham

2014 (estimate) $2.47
2013 $2.74
2012 $3.34
2011 $3.09
2010 $2.96
2009 $2.79

Dividend History
ABT Dividend Chart

ABT Dividend data by YCharts


Abbott Labs is suitable for the Enterprising Investor but not the Defensive Investor, who is concerned with the low current ratio and the lack of sufficient earnings growth over the last ten years.  The Enterprising Investor is only concerned with the lack of earnings growth over the last five years.  As a result, Enterprising Investors following the ModernGraham approach based on Benjamin Graham’s methods should feel comfortable proceeding with further research into the company and comparing it to other opportunities through a review of ModernGraham’s valuation of Johnson & Johnson (JNJ) and ModernGraham’s valuation of Medtronics (MDT).  As for a valuation, the company appears to be overvalued after seeing its EPSmg (normalized earnings) drop from $2.96 in 2010 to only an estimated $2.47 in 2014.  This demonstrated lack of growth does not support the market’s implied estimate of 3.83% earnings growth and leads the ModernGraham valuation model, based on Benjamin Graham’s formula, to return an estimate of intrinsic value below the market price at this time.

The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects.  What do you think?  What value would you put on Abbott Labs (ABT)?  Where do you see the company going in the future?  Is there a company you like better?  Leave a comment on our Facebook page or mention @ModernGraham on Twitter to discuss.

Be sure to review the previous ModernGraham Valuations of Abbott Labs (ABT)!

Disclaimer:  The author did not hold a position in Analog Devices Inc. (ADI) or any other company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours. Logo taken from wikipedia; this article is not affiliated with the company in any manner.






Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.